Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $9.4 million.

  • Century Therapeutics' Non-cash Items rose 7610.22% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 7610.22%. This contributed to the annual value of $16.1 million for FY2024, which is 30997.91% up from last year.
  • Century Therapeutics' Non-cash Items amounted to $9.4 million in Q3 2025, which was up 7610.22% from $8.0 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Non-cash Items peaked at $30.8 million during Q1 2022, and registered a low of $2.8 million during Q2 2022.
  • For the 4-year period, Century Therapeutics' Non-cash Items averaged around $10.5 million, with its median value being $5.7 million (2025).
  • Examining YoY changes over the last 5 years, Century Therapeutics' Non-cash Items showed a top increase of 75986.1% in 2023 and a maximum decrease of 8978.05% in 2023.
  • Century Therapeutics' Non-cash Items (Quarter) stood at $3.2 million in 2022, then increased by 22.57% to $3.9 million in 2023, then skyrocketed by 309.98% to $16.1 million in 2024, then tumbled by 41.7% to $9.4 million in 2025.
  • Its Non-cash Items stands at $9.4 million for Q3 2025, versus $8.0 million for Q2 2025 and $5.7 million for Q1 2025.